Online inquiry

IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14477MR)

This product GTTS-WQ14477MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Dementia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14477MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9336MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ508MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ14361MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ9891MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ7773MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ10288MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ12227MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ2126MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW